AbbVie

Key TakeawaysELAHERE offers a targeted therapy option, potentially improving survival outcomes for FR-positive, platinum-resistant ovarian cancer patients. The VENTANA FOLR1 assay facilitates precise...

Key TakeawaysEmraclidine's tolerability supports its continued investigation in the neuroscience pipeline. The negative trial outcome necessitates a reassessment of dosage or trial design...

Key TakeawaysVYALEV, the first FDA-approved 24-hour subcutaneous levodopa infusion therapy, promises to improve motor fluctuation management in advanced Parkinson’s patients. The Neria Guard...

Key TakeawaysBOTOX® Cosmetic becomes the first FDA-approved neurotoxin for treating moderate to severe vertical platysma bands in the neck and jawline. This approval...

Key FindingsTavapadon met the primary endpoint in the pivotal Phase 3 TEMPO-1 trial, demonstrating significant improvement in MDS-UPDRS Parts II and III combined...

Key HighlightsTelisotuzumab Vedotin (Teliso-V) is an investigational antibody-drug conjugate (ADC) aimed at treating previously treated non-squamous non-small cell lung cancer (NSCLC) patients with...

Key TakeawaysTavapadon has shown significant improvements in motor function for early-stage Parkinson's disease patients, achieving both primary and secondary endpoints in AbbVie's Phase...

Key TakeawaysJUVÉDERM® VOLUMA® XC, the first and only FDA-approved hyaluronic acid filler for temple hollowing, is now available across the U.S. Over 85%...

Key TakeawaysThe Measure Up 1 and Measure Up 2 Phase 3 studies evaluated upadacitinib's efficacy in head and neck atopic dermatitis. Patients receiving...

Key TakeawaysElahere (mirvetuximab soravtansine) is designed to treat adults with FR-alpha–positive epithelial ovarian, fallopian tube, and primary peritoneal cancers that are resistant to...

Schizophrenia is a complex and debilitating condition, affecting millions worldwide with symptoms ranging from hallucinations and delusions to social withdrawal and cognitive impairments. As...

US pharma major AbbVie (NYSE: ABBV) has submitted applications for a new indication to the US Food and Drug Administration (FDA) and European Medicines...

Ulcerative colitis (UC) treatment has advanced with the Food and Drug Administration’s (FDA) approval of AbbVie’s Skyrizi (risankizumab-rzaa) for adults with moderately to severely...

Antibody-drug conjugates (ADCs) ABBV-400 and ABBV-706 were the focus of new data presented by AbbVie at this year's American Society of Clinical Oncology (ASCO)...

Arthritis treatment with upadacitinib (Rinvoq) by Abbvie has been approved by the U.S. Food and Drug Administration (FDA) for pediatric patients with juvenile idiopathic...